http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박강근,김한철,최영화 대구대학교 2006 대구대학교 학술논문집 Vol.1 No.2
캐이블 구조물은 여러 가지 형태를 가진 대공간 구조계에 적용되고 재료에 대해서도 효과적으로 적용된다. 캐이블 구조의 재료적인 특성은 축방향 강성이 크고 휨강성은 적다. 또한 케이블 구조는 초기에는 불안정 구조물이다. 이러한 유연 구조물은 기하학적으로 비선형을 고려하여야 하고 초기에 불안정 구조물이고 대변위 현상이 발생되기 때문에 구조해석을 수행하기 전의 평행된 형태를 연구하여야 한다. 비선형 정적해석은 Total Lagrangian 식과 수정된 Newton Raphson 법을 이용하였다. 본 연구에서는 케이블 돔의 변형형태를 해석하고 비선형 유한요소법으로 케이블 부재의 기하하적 비선형 해석을 하였다.
Choi-Kwon, Smi,Han, Sung W.,Kwon, Sun U.,Kang, Dong-Wha,Choi, Ji M.,Kim, Jong S. Ovid Technologies Wolters Kluwer -American Heart A 2006 Stroke Vol.37 No.1
<P>BACKGROUND AND PURPOSE: The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances. METHODS: Stroke patients (152) who had poststroke depression (PSD), emotional incontinence (PSEI), or anger proneness (PSAP) were studied. PSD was evaluated by Beck Depression Inventory and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, PSEI by Kim's criteria, and PSAP was assessed by Spielberger Trait Anger Scale. Subjects were randomly given either fluoxetine 20 mg/day (n=76) or placebo (n=76) for 3 months. Follow-up evaluations were done 1, 3, and 6 months after the beginning of the treatment. The primary outcome measurement was the scores of emotional disturbances at each follow-up assessment. The secondary outcome measurements were the percentage changes of the scores and the subjective responses of the patients. RESULTS: Although patients in the fluoxetine group more often dropped out because of adverse effects, fluoxetine administration was generally safe. Fluoxetine significantly improved PSEI and PSAP, whereas no definitive improvement of PSD was found. Improvement of PSAP was noted even at 3 months after the discontinuation of the treatment. CONCLUSIONS: Fluoxetine is efficacious in the treatment of PSEI and PSAP. Its effect on PSD is not solidly confirmed.</P>
Kang, Chan Woo,Jang, Kang Won,Sohn, Jinyoung,Kim, Sung-Moo,Pyo, Kyoung-Ho,Kim, Hwan,Yun, Mi Ran,Kang, Han Na,Kim, Hye Ryun,Lim, Sun Min,Moon, Yong Wha,Paik, Soonmyung,Kim, Dae Joon,Kim, Joo Hang,Cho, American Association for Cancer Research 2015 Molecular Cancer Therapeutics Vol.14 No.10
<P><I>RET</I> rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in <I>RET</I>-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in <I>RET</I>-rearranged LADC. Using structural modeling and <I>in vitro</I> analysis, we demonstrated that dovitinib induced cell-cycle arrest at G<SUB>0</SUB>–G<SUB>1</SUB> phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in <I>RET</I>-rearranged LC-2/ad cells. Strong antitumor effect of dovitinib was observed in an LC-2/ad tumor xenograft model. To identify the acquired resistance mechanisms to dovitinib, LC-2/ad cells were exposed to increasing concentrations of dovitinib to generate LC-2/ad DR cells. Gene-set enrichment analysis of gene expression and phosphor-kinase revealed that Src, a central gene in focal adhesion, was activated in LC-2/ad DR cells. Saracatinib, an src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells. Taken together, these findings suggest that dovitinib can be a potential therapeutic option for <I>RET</I>-rearranged LADC, in which acquired resistance to dovitinib can be overcome by targeting Src. <I>Mol Cancer Ther; 14(10); 2238–48. ©2015 AACR</I>.</P>
Kim, Sung-Moo,Kim, Hwan,Jang, Kang Won,Kim, Min Hwan,Sohn, Jinyoung,Yun, Mi Ran,Kang, Han Na,Kang, Chan Woo,Kim, Hye Ryun,Lim, Sun Min,Moon, Yong Wha,Kim, Joo Hang,Paik, Soonmyung,Cho, Byoung Chul American Association for Cancer Research 2016 Molecular Cancer Therapeutics Vol.15 No.7
<P>Although treatment of BRAF V600E-mutant non-small cell lung cancer (NSCLCV600E) with GSK2118436 has shown an encouraging efficacy, most patients develop resistance. To investigate the mechanisms of acquired resistance to GSK2118436 in NSCLCV600E, we established GSK2118436-resistant (GSR) cells by exposing MV522 NSCLCV600E to increasing GSK2118436 concentrations. GSR cells displayed activated EGFR-RAS-CRAF signaling with upregulated EGFR ligands and sustained activation of ERK1/2, but not MEK1/2, in the presence of GSK2118436. Treatment of GSR cells with GSK2118436 enhanced EGFR-mediated RAS activity, leading to the formation of BRAF-CRAF dimers and transactivation of CRAF. Interestingly, sustained activation of ERK1/2 was partly dependent on receptor-interacting protein kinase-2 (RIP2) activity, but not on MEK1/2 activity. Combined BRAF and EGFR inhibition blocked reactivation of ERK signaling and improved efficacy in vitro and in vivo. Our findings support the evaluation of combined BRAF and EGFR inhibition in NSCLCV600E with acquired resistance to BRAF inhibitors. (C) 2016 AACR.</P>
Hong-Yul Seo,Tae-Woo Kim,Ki-Gyung Kim,Tae-Wha Kang,Seon-Yi Kim,Jinhan Kim 한국응용곤충학회 2016 한국응용곤충학회 학술대회논문집 Vol.2016 No.04
The Ministry of Environment in Korea published 'The Compilation of National List of Indigenous Insect Species of the Korean Peninsula' in 1996 including 11,853 species. The National Institute of Biological Resources (NIBR) originally compiled the national species list of insects to establish a national inventory of endemic biological assets with the joined efforts from all distinguished Korean taxonomists since 2008. For the convenience of scores of professional taxonomic groups participating in the project concurrently, the NIBR has developed the NIBR inventory description method and inventory system from 2008 to 2016. For nine years in this study, the NIBR has established the national insect inventory of 16,558 species including Collembola. The insect fauna of the Korean Peninsula comprises 565 families from 30 orders. The largest orders are Coleoptera (110 families, 4,318 species), Lepidoptera (67 families, 3,733 species), Hymenoptera (61 families, 3,151 species), Hemiptera (88 families, 2,013 species) and Diptera (79 families, 1,944 species). The fractions of the main insect orders in the fauna of the Korean peninsula correspond to those in the Holarctic temperate zone. And totally 13 volumes of national list of insect species in Korea were published.
Silent new ischemic lesions after index stroke and the risk of future clinical recurrent stroke
Kang, Dong-Wha,Han, Moon-Ku,Kim, Hye-Jin,Sohn, Hoyon,Kim, Bum Joon,Kwon, Sun U.,Kim, Jong S.,Warach, Steven Ovid Technologies (Wolters Kluwer) - American Acad 2016 Neurology Vol.86 No.3
<P>Objective:To test whether a silent new ischemic lesion (SNIL) on MRI after stroke predicted future recurrent ischemic stroke or vascular events.Methods:In this prospective study, we analyzed data from patients presenting with acute ischemic stroke who underwent MRI <24 hours and 5 and 30 days after symptom onset. The presence of a SNIL at 5 (5D-SNIL) and 30 (30D-SNIL) days was determined on diffusion-weighted and fluid-attenuated inversion recovery images. Patients were contacted every 3-6 months to identify recurrent clinical events. The log-rank test and Cox proportional hazard model were used to estimate the hazard ratio of recurrent ischemic stroke and composites of recurrent ischemic stroke, transient ischemic attack, acute coronary syndrome, and vascular death.Results:The 5D- and 30D-SNILs were found in 24.4% (66/270) and 7.4% (19/256) of patients. During the 5-year follow-up, clinical events were observed in 42 patients (15.6%). The 5D- and 30D-SNIL independently predicted recurrent ischemic stroke (hazard ratio [95% confidence interval] 2.9 [1.3-6.4] and 9.6 [4.1-22.1], respectively) and composite vascular events (2.4 [1.3-4.5] and 6.1 [3.1-12.4], respectively).Conclusions:Patients with a SNIL within the first few weeks after index stroke have an increased risk of recurrent ischemic stroke or vascular events. The presence of a SNIL on MRI could serve as a surrogate endpoint for clinical recurrence in secondary prevention clinical trials.</P>